A Phase 1/1b, Open-Label Multi-Center Two Part Study Of Setd2 Inhibitor Ezm0414 In Subjects With Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Diffuse Large B Cell Lymphoma